دورية أكاديمية
أعرض في EDS

Butyrate Reduces HFD-Induced Adipocyte Hypertrophy and Metabolic Risk Factors in Obese LDLr-/-.Leiden Mice.

التفاصيل البيبلوغرافية
العنوان: Butyrate Reduces HFD-Induced Adipocyte Hypertrophy and Metabolic Risk Factors in Obese LDLr-/-.Leiden Mice.
المؤلفون: Pelgrim CE; Donders Institute for Brain, Cognition and Behaviour, Preclinical Imaging Centre, Department of Anatomy, Radboud University Medical Center, 6525 EZ Nijmegen, The Netherlands. charlottepelgrim@gmail.com., Franx BAA; Donders Institute for Brain, Cognition and Behaviour, Preclinical Imaging Centre, Department of Anatomy, Radboud University Medical Center, 6525 EZ Nijmegen, The Netherlands. bart.franx@gmail.com., Snabel J; Department of Metabolic Health Research, Netherlands Organisation for Applied Scientific Research (TNO), 2301 CE Leiden, The Netherlands. jessica.snabel@tno.nl., Kleemann R; Department of Metabolic Health Research, Netherlands Organisation for Applied Scientific Research (TNO), 2301 CE Leiden, The Netherlands. robert.kleemann@tno.nl., Arnoldussen IAC; Donders Institute for Brain, Cognition and Behaviour, Preclinical Imaging Centre, Department of Anatomy, Radboud University Medical Center, 6525 EZ Nijmegen, The Netherlands. ilse.arnoldussen@radboudumc.nl., Kiliaan AJ; Donders Institute for Brain, Cognition and Behaviour, Preclinical Imaging Centre, Department of Anatomy, Radboud University Medical Center, 6525 EZ Nijmegen, The Netherlands. Amanda.Kiliaan@radboudumc.nl.
المصدر: Nutrients [Nutrients] 2017 Jul 07; Vol. 9 (7). Date of Electronic Publication: 2017 Jul 07.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Publishing Country of Publication: Switzerland NLM ID: 101521595 Publication Model: Electronic Cited Medium: Internet ISSN: 2072-6643 (Electronic) Linking ISSN: 20726643 NLM ISO Abbreviation: Nutrients Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI Publishing
مواضيع طبية MeSH: Adipocytes/*pathology , Butyric Acid/*administration & dosage , Diet, High-Fat/*adverse effects , Obesity/*complications , Receptors, LDL/*deficiency, Adipokines/blood ; Adipose Tissue/physiopathology ; Animals ; Cell Size ; Diabetes Mellitus, Type 2/etiology ; Diabetes Mellitus, Type 2/prevention & control ; Hypertrophy ; Insulin/blood ; Macrophages/pathology ; Male ; Mice ; Mice, Knockout ; Obesity/physiopathology ; Receptors, LDL/genetics ; Receptors, LDL/physiology ; Risk Factors
مستخلص: Adipose tissue (AT) has a modulating role in obesity-induced metabolic complications like type 2 diabetes mellitus (T2DM) via the production of so-called adipokines such as leptin, adiponectin, and resistin. The adipokines are believed to influence other tissues and to affect insulin resistance, liver function, and to increase the risk of T2DM. In this study, we examined the impact of intervention with the short-chain fatty acid butyrate following a high-fat diet (HFD) on AT function and other metabolic risk factors associated with obesity and T2DM in mice during mid- and late life. In both mid- and late adulthood, butyrate reduced HFD-induced adipocyte hypertrophy and elevations in leptin levels, which were associated with body weight, and cholesterol and triglyceride levels. HFD feeding stimulated macrophage accumulation primarily in epididymal AT in both mid- and late life adult mice, which correlated with liver inflammation in late adulthood. In late-adult mice, butyrate diminished increased insulin levels, which were related to adipocyte size and macrophage content in epididymal AT. These results suggest that dietary butyrate supplementation is able to counteract HFD-induced detrimental changes in AT function and metabolic outcomes in late life. These changes underlie the obesity-induced elevated risk of T2DM, and therefore it is suggested that butyrate has potential to attenuate risk factors associated with obesity and T2DM.
Competing Interests: The authors declare no conflict of interest.
References: Int J Obes Relat Metab Disord. 2004 Feb;28(2):307-13. (PMID: 14724655)
Nat Med. 2002 Nov;8(11):1288-95. (PMID: 12368907)
PLoS One. 2012;7(4):e35835. (PMID: 22558236)
Atherosclerosis. 2003 Feb;166(2):387-94. (PMID: 12535753)
J Lipid Res. 2005 Nov;46(11):2347-55. (PMID: 16150820)
Nat Rev Endocrinol. 2015 Oct;11(10):577-91. (PMID: 26260141)
J Clin Invest. 1983 Jun;71(6):1523-35. (PMID: 6345584)
PLoS One. 2012;7(4):e35240. (PMID: 22506074)
Diabetes Metab. 2008 Feb;34(1):2-11. (PMID: 18093861)
Diabetes. 1999 Jan;48(1):94-8. (PMID: 9892227)
J Clin Endocrinol Metab. 2009 May;94(5):1810-7. (PMID: 19223523)
Nature. 2012 Oct 4;490(7418):55-60. (PMID: 23023125)
J Am Diet Assoc. 2002 Jul;102(7):993-1000. (PMID: 12146567)
Arch Neurol. 2004 May;61(5):661-6. (PMID: 15148141)
PLoS One. 2014 Sep 24;9(9):e108564. (PMID: 25251243)
Med Hypotheses. 2010 Oct;75(4):350-2. (PMID: 20381974)
Neurobiol Aging. 2004 Mar;25(3):333-40. (PMID: 15123339)
Proc Natl Acad Sci U S A. 2015 Dec 22;112(51):15731-6. (PMID: 26644559)
Diabetes Care. 2012 Jun;35(6):1364-79. (PMID: 22517736)
Arch Neurol. 2005 Oct;62(10):1556-60. (PMID: 16216938)
Int J Obes (Lond). 2016 Apr;40(4):675-84. (PMID: 26499443)
PLoS One. 2013 Aug 15;8(8):e72204. (PMID: 23967285)
Genome Biol. 2006;7(10):R100. (PMID: 17076895)
Sci Rep. 2016 Aug 22;6:31542. (PMID: 27545964)
Annu Rev Physiol. 2010;72:219-46. (PMID: 20148674)
J Lipid Res. 2013 Sep;54(9):2325-40. (PMID: 23821742)
Diabetes. 2002 Oct;51(10):2951-8. (PMID: 12351432)
J Clin Endocrinol Metab. 2007 Mar;92(3):1023-33. (PMID: 17164304)
Diabetes. 2015 Jul;64(7):2398-408. (PMID: 25695945)
Front Immunol. 2015 Jun 15;6:308. (PMID: 26124760)
Diabetes Care. 2006 Apr;29(4):775-80. (PMID: 16567814)
J Clin Invest. 2003 Dec;112(12):1821-30. (PMID: 14679177)
Nat Clin Pract Endocrinol Metab. 2009 Mar;5(3):150-9. (PMID: 19229235)
J Nutr Biochem. 2016 Apr;30:177-88. (PMID: 27012634)
Int J Obes (Lond). 2016 Sep;40(9):1416-23. (PMID: 27121255)
Int J Obes (Lond). 2017 Jun;41(6):935-944. (PMID: 28220041)
Am J Clin Nutr. 2005 Mar;81(3):555-63. (PMID: 15755822)
J Endocrinol. 1997 Nov;155(2):191-2. (PMID: 9415044)
PLoS One. 2010 Jul 12;5(7):e11525. (PMID: 20634946)
J Physiol. 2016 Jun 15;594(12 ):3187-207. (PMID: 26926488)
Eur Heart J. 2008 Dec;29(24):2959-71. (PMID: 18775919)
J Alzheimers Dis. 2015;43(3):739-55. (PMID: 25147111)
Cell. 2007 Oct 19;131(2):242-56. (PMID: 17956727)
J Nutr. 2008 Mar;138(3):439-42. (PMID: 18287346)
Int J Mol Sci. 2014 Apr 11;15(4):6184-223. (PMID: 24733068)
Expert Rev Cardiovasc Ther. 2008 Mar;6(3):343-68. (PMID: 18327995)
FASEB J. 1998 Jan;12(1):57-65. (PMID: 9438411)
J Am Osteopath Assoc. 2008 Sep;108(9):518-24. (PMID: 18806081)
Epigenomics. 2015;7(4):669-80. (PMID: 26111036)
PLoS One. 2013;8(2):e56122. (PMID: 23457508)
PLoS One. 2013 Sep 25;8(9):e75290. (PMID: 24086498)
Trends Mol Med. 2002 Sep;8(9):442-7. (PMID: 12223316)
PLoS One. 2017 Jan 11;12 (1):e0169740. (PMID: 28076416)
Diabetes. 2009 Jul;58(7):1509-17. (PMID: 19366864)
Diabetes Care. 2006 Sep;29(9):2102-7. (PMID: 16936160)
Obes Res. 2004 Jan;12(1):114-8. (PMID: 14742849)
Int J Obes Relat Metab Disord. 2004 Nov;28 Suppl 3:S70-4. (PMID: 15543223)
Diabetologia. 2016 Aug;59(8):1760-8. (PMID: 27126803)
PLoS One. 2013 Nov 13;8(11):e80476. (PMID: 24236183)
Mol Nutr Food Res. 2012 Jul;56(7):1081-9. (PMID: 22611002)
Diabetol Metab Syndr. 2012 Sep 19;4(1):42. (PMID: 22992414)
Hippocampus. 2012 Nov;22(11):2095-100. (PMID: 22593080)
PLoS Biol. 2010 Jun 29;8(6):e1000412. (PMID: 20613859)
Chem Biol Interact. 2016 Jul 25;254:124-34. (PMID: 27270450)
فهرسة مساهمة: Keywords: T2DM; adipokines; adipose tissue; butyrate; high-fat diet; macrophages; obesity
المشرفين على المادة: 0 (Adipokines)
0 (Insulin)
0 (Receptors, LDL)
107-92-6 (Butyric Acid)
تواريخ الأحداث: Date Created: 20170708 Date Completed: 20180322 Latest Revision: 20181113
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC5537829
DOI: 10.3390/nu9070714
PMID: 28686216
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6643
DOI:10.3390/nu9070714